Fact-checked by Grok 2 weeks ago

Cerebrovascular disease

Cerebrovascular disease encompasses a range of disorders affecting the vessels that supply the , resulting in impaired cerebral or hemorrhage, which can lead to acute events such as or (TIA) and chronic conditions like . It is a leading cause of morbidity and mortality worldwide, with approximately 12 million incident annually and a lifetime risk of one in four people over age 25. The condition arises from disruptions in vascular integrity or perfusion, ultimately causing neuronal damage due to oxygen and nutrient deprivation or direct injury from bleeding. The two primary types of cerebrovascular disease are ischemic and hemorrhagic strokes, accounting for about 85% and 15% of acute cases, respectively. Ischemic strokes occur when blood flow is blocked by , , or small vessel occlusion (lacunar infarcts), often due to or cardioembolic sources like . Hemorrhagic strokes result from vessel rupture, commonly from hypertension-induced damage, aneurysms, or arteriovenous malformations, leading to intracerebral or subarachnoid . TIAs, a subtype of ischemic event also known as mini-strokes, involve temporary focal ischemia causing neurological symptoms that typically resolve within 60 minutes, with no acute infarction on imaging, and serve as critical warning signs, with 10-15% of untreated patients experiencing a major within three months. Major risk factors include modifiable elements such as (the most prevalent, affecting vessel walls over time), diabetes mellitus, , obesity, dyslipidemia, and atrial fibrillation, alongside non-modifiable factors like age, family history, and prior stroke. In the United States, stroke contributes to 17.5% of cardiovascular disease deaths, with 162,639 fatalities recorded in 2023, ranking it as the fourth leading cause of death at a rate of 39.0 per 100,000 population. Globally, projections indicate a 73.4% rise in cardiovascular mortality, including strokes, by 2050, underscoring the urgent need for prevention strategies. Symptoms typically manifest suddenly as focal neurological deficits, including unilateral weakness or numbness, facial droop, speech difficulties ( or ), vision loss, dizziness, or severe headache in hemorrhagic cases, varying by the affected cerebral artery territory such as the (contralateral ) or ( defects). Diagnosis relies on rapid clinical assessment using tools like the NIH Stroke Scale, followed by —non-contrast to exclude hemorrhage and MRI or CT angiography for vessel evaluation. Treatment for ischemic events emphasizes time-sensitive interventions like intravenous with tissue plasminogen activator within 4.5 hours or endovascular up to 24 hours in select cases, while hemorrhagic management focuses on blood pressure control and surgical evacuation if needed; secondary prevention involves antiplatelet therapy, statins, and lifestyle modifications.

Definition and Classification

Definition

Cerebrovascular disease refers to a group of medical conditions involving dysfunction or of the blood vessels supplying the , which leads to impaired cerebral blood flow or disruption of vessel integrity. These disorders encompass both acute and chronic processes that compromise the cerebral vasculature, potentially resulting in neurological deficits due to ischemia, hemorrhage, or other vascular abnormalities. The terminology has evolved historically, originating from the term "cerebrovascular accident" in the mid-20th century to describe sudden events caused by vascular disruption, but it has since broadened to include non- phenomena such as transient ischemic attacks (TIA) and chronic cerebral hypoperfusion. This expansion reflects advances in understanding the spectrum of vascular contributions to brain pathology, moving beyond the acute focus of earlier classifications like used since . Cerebrovascular disease is distinct from cardiovascular disease, which encompasses pathologies of the heart and systemic blood vessels, as it specifically involves the cerebral circulation. It also differs from non-vascular neurological disorders, such as those caused by degenerative or infectious processes without primary vascular involvement.

Major Types

Cerebrovascular disease encompasses several major types, primarily distinguished by the underlying vascular pathology and the nature of blood flow disruption or vessel rupture. The most prevalent form is ischemic cerebrovascular disease, which occurs when blood flow to the brain is obstructed, leading to tissue damage. This category accounts for approximately 87% of all strokes in the United States. It includes four main subtypes: thrombotic, where a clot forms locally within a cerebral artery often due to atherosclerosis (large-artery); embolic, in which a clot or debris travels from elsewhere in the body, such as the heart, to block a brain vessel (cardioembolic); small-vessel occlusion, affecting penetrating arteries and resulting in lacunar infarcts; and hypoperfusion, resulting from systemic reductions in blood flow, such as during cardiac arrest or severe hypotension, affecting watershed areas of the brain. Hemorrhagic cerebrovascular disease involves bleeding into or around the , comprising about 13% of and carrying a higher mortality risk than ischemic events. It is divided into (ICH), where blood accumulates within brain tissue, and (SAH), where bleeding occurs in the space surrounding the brain. ICH is frequently linked to hypertensive origins, with chronic high weakening small vessel walls, though other causes like amyloid angiopathy contribute in older populations. In contrast, SAH often stems from aneurysmal rupture, where a weakened arterial wall balloons and bursts, releasing blood into the subarachnoid space; less commonly, it arises from arteriovenous malformations or . Beyond these acute forms, other types of cerebrovascular disease include (TIA), a transient episode of neurological dysfunction caused by focal , , or retinal ischemia, with no evidence of acute on such as MRI diffusion-weighted imaging; (CVST), involving clot formation in the brain's venous drainage system, often in younger patients with hypercoagulable states; and vascular malformations such as aneurysms (abnormal dilations prone to rupture) and arteriovenous malformations (tangled vessel networks that can bleed or steal blood flow). Genetic disorders also play a role, exemplified by (CADASIL), a hereditary condition causing progressive small vessel damage and recurrent strokes, and , characterized by progressive stenosis of intracranial arteries leading to collateral vessel formation resembling a "puff of smoke" on . Emerging classifications recognize cerebral small vessel disease (CSVD) as a distinct category within cerebrovascular disease, encompassing chronic pathological changes in small penetrating arteries that lead to lacunar infarcts (small cavities from prior ischemia) and hyperintensities visible on . CSVD is increasingly viewed as a major contributor to vascular and disorders, distinct from larger vessel ischemic events.

Risk Factors and Causes

Modifiable Risk Factors

stands as the leading modifiable risk factor for cerebrovascular disease, contributing to approximately 50-60% of the population-attributable risk for ischemic through mechanisms such as endothelial damage, increased , and promotion of . Elevated exerts high intraluminal pressure on vessel walls, leading to and smooth muscle alterations that impair vascular integrity and facilitate formation. According to the 2025 AHA/ACC Guideline, the recommended target for adults to mitigate risk is less than 130/80 mm Hg, with more intensive control (systolic <120 mm Hg) considered for select high-risk individuals based on tolerability and comorbidities. Diabetes mellitus significantly elevates the risk of cerebrovascular disease, with individuals having poorly controlled diabetes (e.g., HbA1c >7%) facing a 2- to 4-fold increased likelihood of compared to those without the condition, primarily due to accelerated and microvascular damage. , characterized by elevated (LDL) cholesterol levels above 100 mg/dL, further compounds this risk by promoting plaque buildup in cerebral arteries. , often intertwined with these metabolic disturbances, amplifies stroke susceptibility through and inflammatory pathways, with greater than 30 kg/m² associated with heightened ischemic events. Smoking is a potent modifiable factor, with current smokers exhibiting approximately a 2-fold higher of than nonsmokers, driven by a dose-response relationship where heavier consumption (e.g., ≥15 cigarettes per day) exacerbates endothelial injury and prothrombotic states. Excessive consumption follows a similar dose-response pattern, with heavy intake (more than 2 drinks per day) increasing by promoting and atrial arrhythmias, whereas light-to-moderate levels may confer minimal or context-dependent benefits for ischemic subtypes. Atrial fibrillation and other cardioembolic sources represent critical modifiable risks, as alone confers a 3- to 5-fold elevated risk through stasis-induced formation in the left atrial appendage. Poor dietary habits, such as high-sodium intake exceeding 2,300 mg per day, foster and , thereby heightening cerebrovascular vulnerability. Physical inactivity, defined as less than 150 minutes of moderate aerobic activity weekly, promotes sedentary-induced and , independently raising incidence by up to 30%.

Non-Modifiable Risk Factors

Non-modifiable risk factors for cerebrovascular disease encompass inherent characteristics that cannot be altered through lifestyle or medical interventions, significantly influencing disease susceptibility. Age represents the most potent non-modifiable risk factor, with the incidence of stroke approximately doubling for each successive decade after age 55 years. This age-related escalation reflects cumulative vascular wear and reduced physiological reserve, accounting for roughly three-quarters of all strokes occurring in individuals over 65. Sex also plays a key role, with men exhibiting higher stroke incidence rates than women under age 75, largely due to earlier onset of vascular pathology; however, post-menopausal women experience a convergence and eventual surpassing of rates after age 75, attributable to longer life expectancy and hormonal changes. Ethnicity contributes to disparities in cerebrovascular disease burden, with facing over twice the stroke mortality risk compared to under age 75, driven by higher prevalence of underlying vascular vulnerabilities. Similarly, South Asian populations demonstrate a 1.5-fold elevated risk of stroke relative to Europeans, linked to distinct genetic and physiological profiles. Genetic predispositions further amplify susceptibility, as variants in the apolipoprotein E (APOE) gene—particularly the ε4 allele—increase the odds of ischemic stroke by promoting atherogenesis and impaired . Family history underscores the hereditary component, where shared genetic traits elevate risk beyond general population levels; for instance, congenital anomalies or inherited disorders heighten vulnerability. , an autosomal dominant condition causing severely elevated from birth, substantially raises the likelihood of premature cerebrovascular events, including ischemic stroke. , another inherited , confers a markedly increased risk of both ischemic and hemorrhagic strokes due to vaso-occlusive crises and endothelial damage, affecting up to 11% of children with the severe form by adolescence. A prior cerebrovascular event, such as a (TIA) or , serves as a critical non-modifiable predictor of recurrence, with individuals having a history of TIA facing nearly 10 times the risk of subsequent stroke compared to those without such events. These fixed risks often compound with modifiable factors, such as , to synergistically heighten overall cerebrovascular vulnerability.

Pathophysiology

Vascular Mechanisms

Cerebrovascular disease encompasses a range of conditions arising from disruptions in cerebral integrity and function, primarily through pathological changes in the vascular walls and blood flow dynamics. These mechanisms include , , , , and hypoperfusion, each contributing to vessel occlusion, narrowing, or rupture that impairs cerebral . Understanding these processes is essential, as they form the foundational vascular pathologies preceding tissue ischemia or hemorrhage. Atherosclerosis is a chronic inflammatory condition characterized by the accumulation of lipids, particularly low-density lipoprotein (LDL), within the arterial intima, initiating plaque formation. This process begins with the infiltration and oxidation of LDL particles, which are trapped by proteoglycans and taken up by macrophages to form foam cells, leading to fatty streaks that evolve into fibrous plaques over decades. In the context of , such as the carotid and vertebrobasilar systems, plaque buildup causes progressive , narrowing the vessel lumen and reducing blood flow; for instance, advanced plaques in the can lead to critical exceeding 70%. Plaque rupture occurs when the thin fibrous cap overlying a lipid-rich necrotic core breaks, exposing thrombogenic material and triggering acute , a key event in ischemic cerebrovascular events. drives this progression, involving cytokines like interleukin-1 (IL-1) and monocyte chemoattractant protein-1 (MCP-1), which recruit immune cells and exacerbate vessel wall damage. Thromboembolism involves the formation and migration of blood clots that occlude , often governed by of stasis, hypercoagulability, and endothelial injury. Stasis arises from reduced blood flow, such as in where irregular contractions promote pooling in the left atrial appendage, fostering development. Hypercoagulability results from imbalances in factors, including elevated fibrinogen or conditions like that increase clotting tendency. Endothelial injury, commonly from atherosclerotic plaques or trauma, exposes subendothelial collagen, activating platelets and the cascade. Emboli typically originate from cardiac sources, such as thrombi in the left ventricle post-myocardial infarction or on abnormal valves in , dislodging to occlude distal cerebral vessels. Arterial sources include in-situ on atherosclerotic lesions in the or carotid arteries, leading to artery-to-artery embolization. Vasculitis refers to inflammation of walls, causing weakening, thickening, or , and can be primary or secondary in nature. Primary vasculitis, such as (GCA), is an idiopathic granulomatous process primarily affecting large and medium-sized arteries like the temporal and vertebral branches, driven by T-cell mediated immune dysregulation and release (e.g., IL-6), resulting in intimal and luminal narrowing. GCA predominantly occurs in individuals over 50 and is associated with genetic factors like HLA-DRB1*04. Secondary vasculitis arises from underlying conditions, including infections (e.g., hepatitis B-associated ), autoimmune diseases (e.g., ), or drug hypersensitivity, leading to immune complex deposition and vessel wall damage. Arterial dissection involves a tear in the intimal layer, allowing blood to enter the vessel wall and form a false lumen, which can propagate to cause , , or ; common in extracranial carotid or vertebral arteries, it is often precipitated by trauma, connective tissue disorders like Ehlers-Danlos syndrome, or spontaneous hemodynamic stress. Hypoperfusion manifests as global or focal reductions in cerebral blood flow, compromising oxygen delivery without direct vessel occlusion by clot or plaque. Global hypoperfusion typically stems from systemic , such as during , severe , or excessive antihypertensive therapy, leading to widespread cerebral ischemia, particularly in watershed zones between major arterial territories. Focal hypoperfusion occurs distal to significant stenosis, as in bilateral narrowing from , where compensatory autoregulation fails, reducing pressure in border-zone regions supplied by the anterior, middle, and posterior .

Cerebral Ischemia and Hemorrhage Processes

Cerebrovascular disease encompasses processes where vascular disruptions lead to cerebral ischemia or hemorrhage, primarily manifesting as subtypes. In ischemic , vessel occlusion—either thrombotic from local or embolic from distant sources—reduces cerebral blood flow below critical thresholds, such as <10 mL/100 g/min for the infarct core of irreversibly damaged tissue reliant on the affected artery. Surrounding this core is the ischemic penumbra, a region of hypoperfused but viable tissue sustained by collateral circulation, which risks progression to if reperfusion is delayed due to ongoing and spreading depolarization. This penumbra represents a therapeutic target, as timely intervention can salvage it, underscoring the principle that "time is brain" in acute management. The therapeutic window for interventions like intravenous tissue plasminogen activator (tPA) is limited to 4.5 hours from symptom onset, based on evidence showing increased odds of favorable outcomes ( 1.31, 95% 1.10-1.56) without excess mortality, though with a higher risk of symptomatic . Large vessel strokes, such as those involving the , are strongly linked to and risk factors like male sex, , prior , and elevated cholesterol, often presenting with more gradual onset and territorial infarcts. In contrast, cardioembolic strokes, typically from cardiac sources like , show inverse associations with these factors—being more common in females, nonsmokers, and those with lower cholesterol—and tend to cause abrupt, severe deficits due to abrupt vessel occlusion. Reperfusion, while essential, can paradoxically exacerbate damage through ischemia-reperfusion injury, where restored blood flow triggers excessive production, leading to , , and that worsen neuronal death. This process also involves from glutamate release and calcium overload, amplifying mitochondrial dysfunction and potentially causing hemorrhagic transformation, as observed in up to 6.4% of tPA-treated patients versus 0.3% in controls. Hemorrhagic stroke arises from vessel rupture, often hypertensive or due to underlying fragility, resulting in formation that compresses brain tissue and elevates . expansion occurs in about one-third of cases within the first 3 hours, driven by continued bleeding and associated with neurological deterioration, perihematomal peaking at 5-6 days, and poor prognosis factors like volume exceeding 30 mL or intraventricular extension. In lobar hemorrhages, plays a key role by depositing in vessel walls, rendering them fragile and prone to rupture in cortical regions, particularly posteriorly, with a recurrence rate of approximately 21%.

Small Vessel Involvement

Cerebral small vessel disease (CSVD) encompasses pathological changes in the small arteries, arterioles, venules, and capillaries of the brain, leading to characteristic neuroimaging features. According to the Standards for Reporting Vascular Changes on Neuroimaging version 2 (STRIVE-v2), key markers include lacunar infarcts (small cavities measuring 3-15 mm resulting from prior ischemic events), white matter hyperintensities (patchy or confluent areas of T2/FLAIR hyperintensity indicating ischemia or demyelination), cerebral microbleeds (small hypointense lesions on susceptibility-weighted imaging suggestive of hemosiderin deposition), and enlarged perivascular spaces (fluid-filled spaces around vessels appearing as hyperintense on T2-weighted images). These markers are standardized for research and clinical assessment as of 2023 updates, with ongoing validation in 2025 studies confirming their reliability in detecting microvascular pathology. The pathogenesis of CSVD involves multiple interconnected mechanisms, prominently featuring —a hyaline deposition and in vessel walls leading to luminal narrowing— impairing and promoting , and disruption of the that allows leakage of proteins and immune cells into . accelerates these processes by inducing shear stress and oxidative damage to endothelial cells, while aging contributes through cumulative vascular stiffening and reduced regenerative capacity, exacerbating and loss. further links to BBB breakdown, as reduced integrity facilitates perivascular and neurodegeneration. Emerging research also implicates impairment and genetic factors like APOE ε4 in exacerbating CSVD-related neurodegeneration. Clinically, CSVD accounts for approximately 20-25% of all ischemic , often manifesting as lacunar infarcts, and serves as a major contributor to through chronic microvascular ischemia and hemorrhage. Recent 2025 analyses highlight CSVD's role in silent brain injury, where subclinical lesions accumulate without overt symptoms, progressively impairing and contributing to approximately 45–50% of cases. Progression of CSVD is assessed using cumulative burden scoring systems that quantify overall microvascular damage. The Fazekas scale, a widely adopted visual rating tool, grades hyperintensities on a 0-3 scale (0: absent; 1: punctate; 2: early confluent; 3: confluent), providing a simple metric for tracking ischemic burden over time. Composite scores, such as the total CSVD burden (ranging 0-4 points for presence of lacunes, severe hyperintensities via Fazekas ≥2, microbleeds, and enlarged perivascular spaces), enable prediction of cognitive decline and recurrence, with higher scores correlating to accelerated progression. These models emphasize the additive impact of multiple markers in forecasting clinical outcomes.

Clinical Presentation

Acute Signs and Symptoms

Cerebrovascular events, such as ischemic stroke and , typically present with a sudden onset of focal neurological deficits attributable to disruption in a specific vascular territory of the . These deficits arise from ischemia or hemorrhage impairing neuronal function and include weakness or paralysis on one side of the body (), impairment in language production or comprehension (), and loss of vision in half of the (). The FAST acronym, developed by the , aids in rapid identification: Face drooping (asymmetry during smiling), Arm weakness (inability to raise both arms evenly), Speech difficulty (slurred or unclear words), and Time to call emergency services. Non-specific symptoms may accompany these focal signs and can complicate early recognition. A sudden, severe headache often signals hemorrhagic , described as "thunderclap" onset with possible and . Sudden or altered mental status, including difficulty understanding or responding, occurs frequently and reflects diffuse cerebral involvement. Seizures manifest in the acute phase in 2-6% of ischemic strokes and up to 15% of hemorrhagic cases, typically within the first 24 hours and more common in cortical lesions. Transient ischemic attacks (TIAs), or "mini-strokes," mimic symptoms but resolve completely, usually within 1 hour and always by 24 hours, due to temporary ischemia without permanent . The stratifies post-TIA risk (low <4, moderate 4-5, high ≥6) using age (≥60 years: 1 point), blood pressure (≥140/90 mmHg: 1 point), clinical features (speech disturbance without weakness: 1 point; weakness: 2 points), duration (10-59 minutes: 1 point; ≥60 minutes: 2 points), and diabetes (1 point). Symptom patterns vary by vascular territory. Anterior circulation events, involving the carotid arteries and middle cerebral artery branches, commonly cause contralateral hemiparesis, aphasia (if dominant hemisphere), and facial droop. Posterior circulation strokes, affecting the vertebrobasilar system, more often present with vertigo, ataxia (unsteadiness or limb incoordination), nausea/vomiting, and visual disturbances like diplopia, though overlap with anterior symptoms can occur.

Chronic Manifestations

Chronic manifestations of cerebrovascular disease often emerge as persistent or progressive sequelae following acute events, encompassing a range of neurological, psychological, and functional impairments that significantly affect quality of life. Cognitive impairment is a prominent long-term outcome, particularly in the form of , which frequently involves executive dysfunction such as difficulties in planning, decision-making, and attention. In , a subtype of vascular dementia resulting from multiple small strokes, cognitive decline typically occurs in a stepwise manner, with abrupt deteriorations corresponding to successive ischemic events rather than a gradual progression. Motor and sensory deficits commonly persist post-stroke, including residual hemiplegia characterized by weakness or paralysis on one side of the body, which can impair mobility and daily activities. Spasticity, an increase in muscle tone leading to stiffness and involuntary contractions, often accompanies hemiplegia and may develop or worsen over time due to upper motor neuron damage. Sensory loss, such as reduced sensation to touch, pain, or temperature on the affected side, further contributes to functional limitations and increases fall risk. Mood and behavioral changes represent another key chronic feature, with post-stroke depression affecting approximately 30-50% of survivors and manifesting as persistent sadness, loss of interest, and fatigue that can endure for months or years. Apathy, marked by diminished motivation and emotional responsiveness, occurs with similar prevalence to depression, around 35%, and often coexists, exacerbating social withdrawal and rehabilitation challenges. Silent manifestations of cerebrovascular disease, particularly asymptomatic cerebral small vessel disease (CSVD), can lead to insidious cognitive decline without overt stroke symptoms, driven by chronic microvascular changes and brain remodeling. Recent 2025 studies highlight how CSVD biomarkers, such as white matter hyperintensities, independently predict gradual deterioration in memory and executive function over years, even in the absence of clinical events. These subclinical processes underscore the importance of early imaging for at-risk populations.

Diagnosis

Clinical Evaluation

The clinical evaluation of suspected cerebrovascular disease begins with a rapid history-taking to establish the onset timing of symptoms, which is critical for determining eligibility for time-sensitive interventions such as . Patients or witnesses are questioned about the last known well time, the abruptness of symptom onset (typically sudden in ), and associated features like headache or vomiting that may suggest hemorrhage. Risk factors are assessed concurrently, including modifiable elements such as , , , and , as well as non-modifiable ones like age and prior stroke history, to contextualize the event and guide further management. This focused history should be completed within minutes of patient arrival to the emergency department, emphasizing brevity to avoid delaying care. The physical examination follows immediately, incorporating vital signs assessment and a targeted neurological evaluation to quantify deficits and localize the lesion. The National Institutes of Health Stroke Scale (NIHSS) is the standard tool for this, a validated 11-item scale scoring from 0 (normal) to 42 (severe impairment) that evaluates consciousness, gaze, visual fields, facial palsy, motor strength, sensory loss, language, dysarthria, neglect, and ataxia. Scores guide severity classification—mild (0-4), moderate (5-15), severe (16-20), or very severe (>20)—and predict outcomes, with higher scores correlating to worse and influencing treatment decisions like endovascular eligibility. The NIHSS is performed within 10 minutes of arrival to facilitate rapid . Neurological examination components include cranial nerve testing for facial weakness or defects, motor evaluation for (graded 0-5 on the NIHSS), sensory assessment for deficits in touch or , and observation if the patient is ambulatory to detect or imbalance. These elements help identify the vascular territory affected, such as involvement in hemiplegic presentations. The exam prioritizes focal deficits over diffuse findings to streamline the process. Differential diagnosis is essential, as up to 30% of suspected cases are mimics; common ones include seizures (presenting with postictal Todd's paralysis), migraines (with aura causing transient focal symptoms), and (inducing confusion or weakness reversible by glucose administration). Distinguishing these relies on details like gradual onset or systemic symptoms, avoiding unnecessary interventions. Urgency protocols underscore the "time is brain" principle, mandating evaluation within the —ideally door-to-needle time under 60 minutes for candidates—to minimize neuronal loss, with every 30-minute delay reducing favorable outcomes by about 10%. Protocols activate teams upon suspicion, prioritizing ABC stabilization and NIHSS before confirmatory imaging.

Diagnostic Imaging

Diagnostic imaging plays a crucial role in confirming and characterizing , distinguishing between ischemic and hemorrhagic events, and assessing . Non-contrast () is the initial imaging modality of choice in acute settings due to its rapid acquisition and high for detecting , exceeding 95% in the hyperacute phase. This modality effectively identifies hyperdense blood within the first few hours of onset, allowing differentiation from ischemic stroke, though it has lower (around 40-60%) for early ischemic changes. Magnetic resonance imaging (MRI), particularly diffusion-weighted imaging (DWI), offers superior sensitivity for acute ischemia, ranging from 88% to 100%, by detecting restricted diffusion in affected brain tissue as early as minutes after symptom onset. DWI is often complemented by apparent diffusion coefficient (ADC) maps to confirm true infarction and rule out mimics like seizures. For hemorrhage, gradient echo or susceptibility-weighted sequences on MRI can detect blood products with high specificity, though MRI is typically reserved for subacute evaluation or when CT is inconclusive. Vascular imaging modalities are essential for evaluating , , or aneurysms contributing to cerebrovascular events. CT (CTA) provides detailed visualization of large vessel , such as in the , with high using intravenous contrast and multiplanar reconstructions. MR (MRA), which avoids , is comparably effective for assessing extracranial and intracranial vessels, particularly in patients with renal impairment. (DSA) remains the gold standard for invasive confirmation of vascular abnormalities, offering the highest resolution for therapeutic planning despite its risks. Advanced imaging techniques enhance the assessment of viability and underlying pathology. Perfusion imaging, via CT perfusion (CTP) or MR perfusion (MRP), quantifies cerebral , , and mean transit time to identify the ischemic penumbra—salvageable surrounding the infarct core—critical for selecting patients for . Recent advancements as of 2025 incorporate (AI) in MRI analysis for cerebral small vessel disease (CSVD), improving automated detection of hyperintensities and lacunes with sensitivities up to 95%, facilitating earlier identification of microvascular changes. Laboratory tests complement imaging by identifying underlying causes and risk factors. profiles, including and international normalized ratio, help exclude coagulopathies in hemorrhagic cases. Lipid panels assess as a stroke risk factor, while levels aid in ruling out cardioembolic sources from acute coronary events. These tests integrate with clinical to guide comprehensive .

Management

Acute Interventions

Acute interventions for cerebrovascular disease focus on rapid restoration of cerebral blood flow in ischemic events or stabilization and control in hemorrhagic cases, aiming to minimize neuronal damage during the hyperacute phase. These time-sensitive measures are guided by established protocols emphasizing eligibility assessment, confirmation, and multidisciplinary coordination to optimize outcomes. In acute ischemic stroke, intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK) is the primary for eligible patients, administered within 4.5 hours of symptom onset to dissolve clots and improve neurological recovery. is dosed at 0.9 mg/kg (maximum 90 mg), with 10% as bolus and remainder infused over 60 minutes; tenecteplase, a reasonable alternative, is given as a single bolus of 0.25 mg/kg (maximum 25 mg) or 0.4 mg/kg (maximum 40 mg) based on recent evidence. Contraindications include recent major , active , or severe uncontrolled (systolic >185 mmHg), as these increase hemorrhage risk. For patients with large vessel occlusions, endovascular mechanical provides an alternative or adjunctive approach, recommended up to 6 hours routinely and extending to 24 hours in select cases with favorable perfusion imaging, significantly reducing disability in responders. Supportive care in ischemic stroke involves immediate to ensure oxygenation, blood glucose control targeting 140-180 mg/dL to prevent hypo- or hyperglycemia-induced injury, and early antiplatelet therapy with aspirin 160-325 mg initiated within 24-48 hours after thrombolysis exclusion to reduce recurrent events. For acute , management is critical to limit expansion, with guidelines recommending acute lowering to a systolic target of 130-140 mmHg in patients presenting with 150-220 mmHg, achieved via continuous infusion of agents like for steady control. Surgical evacuation is indicated for large supratentorial hematomas (>30 mL) using minimally invasive techniques to improve functional outcomes and reduce mortality, particularly when combined with of deterioration; for cerebellar hemorrhages exceeding 15 mL with or , urgent decompression is lifesaving. Supportive measures include rapid reversal of anticoagulation if applicable, normoglycemia maintenance, and prophylaxis in select high-risk cases to support hemodynamic stability. These interventions stabilize the acute phase, facilitating transition to long-term management strategies.

Long-Term Management

Long-term management of cerebrovascular disease focuses on preventing recurrent events, optimizing functional recovery, and addressing modifiable risk factors through a combination of pharmacological, rehabilitative, and procedural interventions. Following the acute phase, antithrombotic is a , tailored to the underlying of the ischemic event. For patients with non-cardioembolic ischemic or high-risk (TIA), dual antiplatelet therapy with aspirin (50-325 mg daily) plus clopidogrel (75 mg daily) is recommended for 21 days, after which monotherapy with either agent is continued indefinitely to reduce the risk of recurrence by approximately 20-30% compared to aspirin alone. In cases of cardioembolic due to , direct oral anticoagulants (DOACs) such as (5 mg twice daily, adjusted for renal function) are preferred over , offering a 20-30% in stroke recurrence while minimizing risk; initiation can occur as early as 48 hours post-event in mild cases. Risk factor modification plays a critical role in sustaining vascular health and averting secondary events. High-intensity therapy, such as 40-80 mg daily, is indicated to achieve cholesterol (LDL-C) levels below 70 mg/dL, which has been shown to decrease major vascular events by 20-25% in patients with recent . Blood pressure control targets a systolic pressure below 130 mm Hg and diastolic below 80 mm Hg using regimens including ACE inhibitors, ARBs, or diuretics, as intensive management reduces recurrent risk by up to 40% compared to less stringent targets. Glycemic control in diabetic patients, aiming for HbA1c ≤7%, incorporates agents like pioglitazone, which further lowers recurrence by 47% in those with . Rehabilitation employs multidisciplinary strategies to harness and restore independence, beginning as early as medically stable in the subacute phase. Physical therapy emphasizes task-specific, repetitive training (e.g., or treadmill walking with body-weight support) to improve motor function, leveraging heightened synaptic remodeling and during the first 3-6 months post-stroke. focuses on through adaptive techniques and strengthening, while speech-language therapy addresses and via intensive, constraint-based interventions, enhancing communication recovery in up to 70% of affected patients. Recent reviews underscore principles, including the promotion of (BDNF) upregulation through enriched environments and virtual reality-assisted practice, which facilitate axonal sprouting and functional reorganization for sustained gains. For select patients with extracranial disease, revascularization procedures mitigate recurrent risk from . (CEA) is recommended for symptomatic of 70-99%, providing a 16% absolute risk reduction in ipsilateral over 5 years, with optimal timing within 2 weeks of the index event in suitable candidates. (CAS) serves as an alternative for those at high surgical risk (e.g., due to comorbidities or ), yielding comparable long-term outcomes to CEA in trials like , though with a slightly higher periprocedural rate. These interventions align with secondary prevention goals by addressing focal atherosclerotic lesions.

Prognosis and Outcomes

Mortality and Morbidity

Cerebrovascular disease, encompassing ischemic and hemorrhagic , carries substantial short-term mortality risks. The 30-day for acute ischemic stroke is approximately 10%, as observed in recent analyses of stroke unit patients in . For hemorrhagic stroke, including intracerebral and subarachnoid subtypes, 30-day case fatality rates are markedly higher, ranging from 35% to 50%, reflecting the severity of vascular rupture and associated injury. Acute morbidity further exacerbates outcomes, with common complications including , which can lead to increased and neurological deterioration; hemorrhagic transformation of ischemic infarcts, occurring in 10–40% of cases (symptomatic in 1–6%), with symptomatic cases associated with worse ; and recurrent stroke-related readmissions within 30 days, which elevate mortality risk by over 3 times (OR 3.6) compared to initial admissions. These complications are linked to impaired and require vigilant in acute settings. Despite these challenges, global age-standardized mortality rates are declining, with a projected 28% reduction from 2021 to 2050 due to improved interventions. Several factors influence these outcomes, notably the Stroke Scale (NIHSS) score at presentation, which strongly correlates with mortality; scores exceeding 20 are associated with significantly poorer short-term prognosis and higher death rates. Globally, mortality variations are pronounced, with age-standardized death rates in low-income countries being 3.6 times higher than in high-income regions, largely attributable to delays in and to timely interventions.

Functional Recovery

Functional recovery after cerebrovascular disease, particularly , is commonly assessed using the (mRS), a validated tool ranging from 0 (no symptoms) to 6 (death) that evaluates independence in daily activities. Approximately 50% of stroke survivors exhibit moderate to severe (mRS score >2) at 6 months post-event, indicating significant long-term dependence on assistance for routine tasks. This metric highlights the variability in outcomes, with many individuals regaining partial independence through , though persistent deficits affect . Several factors influence the trajectory of functional , including younger , smaller infarct size, and initiation of early . Younger patients often demonstrate greater potential for improvement due to enhanced neural reserve and fewer comorbidities, while smaller lesions preserve more viable brain tissue for compensation. Early , starting within the first two weeks, promotes motor and cognitive gains by leveraging the brain's . Recent studies emphasize the role of and brain remodeling in this process, where synaptic reorganization and structural changes in perilesional areas facilitate long-term , as evidenced by 2025 research on cerebellar adaptations post-stroke. Chronic complications further challenge functional recovery, including post-stroke epilepsy affecting 5-10% of survivors, which can exacerbate through recurrent seizures. Post-stroke depression, prevalent in about 30% of cases, impairs and adherence to , often leading to prolonged dependency. Cognitive decline, observed in 30-50% of patients, contributes to difficulties in executive function and , increasing the risk of institutionalization and reducing overall . These issues underscore the need for integrated management to mitigate their impact on . Emerging precision medicine approaches aim to optimize recovery by tailoring to individual genetic markers, such as variants influencing and response. For instance, for polymorphisms in genes like BDNF can guide personalized intensity, potentially improving outcomes in motor and cognitive domains. These strategies, supported by genomic studies, represent a shift toward individualized interventions to enhance functional independence.

Epidemiology

Incidence and Prevalence

Cerebrovascular disease, encompassing conditions such as ischemic stroke, hemorrhagic stroke, and cerebral small vessel disease (CSVD), affects millions worldwide annually. Globally, there were approximately 11.9 million incident strokes in 2021, with projections indicating a substantial rise in the coming decades due to demographic shifts and varying regional prevention efforts. In the United States, the American Heart Association reported about 795,000 new or recurrent strokes in recent estimates, highlighting the persistent burden even in high-resource settings. Prevalence of cerebrovascular disease also varies by subtype and population. Chronic changes like CSVD, a key component of cerebrovascular pathology, affect roughly 5% of individuals at age 50, rising sharply with age to nearly 100% in those over 90, though community-based studies in adults over 50 report overall around 30% for detectable markers. This underscores the insidious nature of subclinical cerebrovascular damage, which contributes to cognitive decline and without acute events. Globally, about 93.8 million people were living with stroke sequelae in 2021. Trends in incidence show divergence by . In high-income countries, age-adjusted rates have declined by approximately 42% since the 1970s, attributable to improved control, reduced , and better . Conversely, low- and middle-income countries (LMICs) face rising burdens, with deaths projected to increase by 50% globally by 2050—from 6.6 million in 2020 to 9.7 million—driven largely by population aging and uneven risk factor management in these regions. Incidence patterns are strongly influenced by age and sex. Stroke risk doubles every decade after age 55, peaking in the 70-80 age group, where the majority of events occur due to cumulative vascular damage. Men exhibit a slight predominance, accounting for 52.6% of incident strokes globally, though this gap narrows in older age groups as women's longevity exposes them to prolonged risk exposure.

Risk Factor Distribution

Cerebrovascular disease risk factors exhibit significant geographic disparities, with prevalence notably higher in compared to . In , affects approximately 33-46% of adults, driven by factors such as , dietary shifts, and limited healthcare access, which correlates with incidence rates roughly twice as high as in populations when age-adjusted. For instance, age-standardized incidence in African regions reaches 94-108 per 100,000, contrasting with lower rates of around 50-70 per 100,000 in , underscoring the role of uncontrolled in elevating vascular event risks across these continents. Socioeconomic factors profoundly influence cerebrovascular disease distribution, with low and levels associated with 1.5- to 2-fold higher incidence compared to higher socioeconomic groups. This disparity arises from reduced access to preventive care, higher prevalence of modifiable risks like and , and delayed treatment, amplifying overall burden in disadvantaged populations. Recent 2025 analyses highlight urban-rural divides, where rural residents face up to 30% higher incidence than counterparts, attributed to poorer and differences in regions like the and . Emerging environmental risks are increasingly contributing to cerebrovascular disease variations, particularly in , where air pollution exposure elevates cerebral small vessel disease (CSVD) markers such as hyperintensities. Annual PM10 levels have been linked to higher CSVD prevalence in East Asian cohorts, with studies in and showing positive associations between fine and evidence of vascular damage, potentially increasing ischemic event risks by promoting . Climate-related factors, including rising temperatures and , further exacerbate this trend; projections for indicate a substantial uptick in heat-related mortality under scenarios, with temperature fluctuations correlating to heightened acute cerebrovascular events. Additionally, post-COVID-19 vascular complications have added 10-20% to relative risks in affected individuals, with long-term data from 2024-2025 revealing doubled odds of ischemic events due to persistent endothelial inflammation and . Demographic breakdowns reveal ethnic variations in risk factor profiles, notably higher diabetes prevalence among Hispanics, which contributes to elevated ischemic stroke events. In the United States, Hispanic populations experience diabetes rates up to 13.4%—nearly double the non-Hispanic white rate—directly linking to 2-fold increased ischemic stroke incidence compared to non-Hispanic whites, mediated through accelerated and poor glycemic control. This disparity is particularly pronounced in Mexican Americans, where diabetes amplifies overall cerebrovascular burden by 37-42% in those under 65 years.

Prevention

Primary Prevention Measures

Primary prevention of cerebrovascular disease focuses on modifiable risk factors to avert the initial occurrence of in at-risk individuals, emphasizing evidence-based strategies that target , , and behavioral contributors. Modifiable factors such as , poor diet, and account for a substantial portion of stroke burden, with interventions yielding significant risk reductions when implemented early. Lifestyle interventions form the cornerstone of primary prevention. Smoking cessation substantially lowers stroke risk; within 5 years of quitting, former smokers achieve a risk level comparable to never-smokers, effectively halving the elevated odds associated with current use. Adopting a , rich in fruits, vegetables, whole grains, nuts, and , reduces incident stroke risk by approximately 12-20% in adherent populations, particularly through improvements in and lipid profiles. Regular , at least 150 minutes per week of moderate-intensity , further mitigates risk by enhancing cardiovascular health and endothelial function, as endorsed by major guidelines. Pharmacological prophylaxis is recommended for high-risk individuals without prior events. Statins are advised for primary prevention in adults aged 40-75 with , LDL ≥190 mg/dL, or a 10-year atherosclerotic risk ≥7.5-10%, reducing incidence through cholesterol lowering. Antihypertensive , often requiring two or more agents, is essential for those with ( ≥130/80 mmHg), as it lowers first-time risk by 30-40% via blood pressure normalization. Low-dose aspirin (75-100 mg daily) may be considered in select primary prevention cases for adults aged 40-59 at elevated cardiovascular risk without increased bleeding propensity, though routine use is not recommended due to hemorrhage concerns. Public health initiatives play a vital role in scaling prevention efforts. screening programs, recommended annually for adults over 40 and every 3-5 years for younger adults, enable early detection and , the leading modifiable risk factor. Awareness campaigns, such as World Stroke Day observed annually on October 29, promote education on symptoms, risk reduction, and healthy behaviors, fostering community-wide adoption of preventive measures. Emerging research in 2025, including reviews on cardio-cerebrovascular , increasingly emphasizes mitigation. mitigation, including reducing exposure to fine (PM2.5), is crucial as short- and long-term exposure elevates risk by promoting and , particularly in urban vulnerable populations. For in high-risk groups like older adults and ethnic minorities, the 2025 American Diabetes Association standards advocate tight glycemic control (HbA1c <7% where safe), alongside and antihypertensive use, to curb cerebrovascular complications.

Secondary Prevention Strategies

Secondary prevention strategies for cerebrovascular disease aim to reduce the risk of recurrent ischemic strokes or other cerebrovascular events in patients who have already experienced an initial episode, such as ischemic stroke, (TIA), or (SAH). These strategies are tailored to the underlying , incorporating therapies, surgical interventions, multidisciplinary care, and targeted monitoring to address modifiable risk factors and prevent progression of vascular pathology. Antithrombotic regimens form the cornerstone of secondary prevention for ischemic and TIA. In patients with (AFib) as the cardioembolic source, long-term oral anticoagulation is recommended to substantially lower recurrence risk; for instance, reduces ischemic and systemic embolism by approximately 67% compared to , while direct oral anticoagulants (DOACs) offer similar efficacy with a more favorable safety profile. For non-cardioembolic ischemic strokes, antiplatelet is preferred over anticoagulation, with guidelines endorsing aspirin (50-325 mg daily), clopidogrel (75 mg daily), or the combination of aspirin and extended-release dipyridamole (25 mg/200 mg twice daily) as first-line options to decrease recurrent vascular events by about 20-25%. Dual antiplatelet with aspirin and clopidogrel is typically limited to the initial 21-90 days post-event for high-risk minor strokes or TIAs, after which single-agent is continued long-term to balance efficacy against bleeding risks. Surgical interventions target specific anatomical risks to prevent recurrence, particularly in cases of extracranial carotid artery disease. Carotid revascularization, via endarterectomy or stenting, is indicated for symptomatic stenosis of 50% or greater, as it significantly reduces ipsilateral stroke risk in appropriately selected patients with recent ischemic symptoms and low perioperative risk. The choice between carotid endarterectomy and stenting depends on factors such as lesion anatomy, patient comorbidities, and operator expertise, with both approaches demonstrating comparable long-term outcomes in randomized trials. Multidisciplinary follow-up is essential for optimizing adherence to preventive measures and promoting sustained modifications. Comprehensive post-event care involves regular visits with neurologists, cardiologists, and specialists to monitor medication compliance, control, and management, alongside coaching on , , and dietary changes, which collectively can reduce recurrent risk by up to 80% when fully implemented. As of 2025, precision approaches such as genetic-guided antiplatelet therapy—particularly CYP2C19 to personalize clopidogrel use in or poor metabolizers—have emerged to enhance and minimize adverse events in secondary prevention. Monitoring protocols are critical for patients with aneurysmal SAH to detect and manage residual or recurrent s. Following securement of the ruptured via clipping or , guidelines recommend serial surveillance, typically with (MRA) or (CTA) every 6-12 months initially, then annually or biennially thereafter, to assess for remnants, recanalization, or growth that could precipitate rebleeding. ultrasonography may complement these for detection in the acute phase, but long-term imaging focuses on structural integrity to guide potential re-intervention.

References

  1. [1]
    Cerebrovascular Disease - StatPearls - NCBI Bookshelf - NIH
    A stroke, or cerebrovascular accident, is an emergency medical condition characterized by an acute compromise of the cerebral perfusion or vasculature.
  2. [2]
    World Stroke Organization: Global Stroke Fact Sheet 2025 - PMC
    There are almost 12 million new strokes each year. Globally, one in four people above age 25 years will have a stroke in their lifetime.
  3. [3]
    Stroke - Causes and Risk Factors | NHLBI, NIH
    May 26, 2023 · Strokes are caused by blocked blood flow to the brain (ischemic stroke) or sudden bleeding in the brain (hemorrhagic stroke).
  4. [4]
    About Stroke - CDC
    Oct 24, 2024 · A stroke, sometimes called a brain attack, occurs when something blocks blood supply to part of the brain or when a blood vessel in the brain bursts.
  5. [5]
    Stroke Facts - CDC
    Oct 24, 2024 · Fast facts. In the United States in 2022, 1 in 6 deaths (17.5%) from cardiovascular disease was due to stroke.1; The death rate for stroke ...
  6. [6]
    Global burden of cardiovascular diseases: projections from 2025 to ...
    Aug 25, 2025 · Between 2025 and 2050, a 90.0% increase in cardiovascular prevalence, 73.4% increase in crude mortality, and 54.7% increase in crude DALYs are projected.Missing: cerebrovascular | Show results with:cerebrovascular
  7. [7]
    Cerebrovascular Disease - Clinical Methods - NCBI Bookshelf - NIH
    Definition. A neurologic symptom or symptom complex caused by cerebral ischemia or hemorrhage is commonly called a cerebrovascular accident (CVA), or stroke. ...
  8. [8]
    Apoplexy, cerebrovascular disease, and stroke: Historical evolution ...
    The term “stroke” (cerebrovascular) appeared first in the ICD-9 (1968).39 The definition of the concept by the World Health Organization (WHO) appeared soon ...
  9. [9]
    Chapter 27: a history of cerebrovascular disease - PubMed
    In the 17th century, Johannes Wepfer, a Swiss physician, first demonstrated that apoplexy was caused by an intracranial hemorrhage; Thomas Willis, an English ...
  10. [10]
    Types of Stroke | Johns Hopkins Medicine
    Strokes are classified as either ischemic or hemorrhagic. Ischemic strokes are caused by blockage of an artery. Hemorrhagic strokes are caused by bleeding ...
  11. [11]
    Embolic Stroke - StatPearls - NCBI Bookshelf - NIH
    Three main mechanisms can cause an ischemic stroke: thrombosis, hypoperfusion, or embolic phenomena.[4] Embolic strokes occur when clots migrate from the ...
  12. [12]
    Hemorrhagic Stroke: Background, Anatomy, Etiology
    Sep 2, 2025 · Intracerebral hemorrhage is more commonly associated with headache, altered mental status, seizures, nausea and vomiting, and significant hypertension.
  13. [13]
    Subarachnoid hemorrhage - Symptoms and causes - Mayo Clinic
    Oct 26, 2024 · A subarachnoid hemorrhage is a type of stroke. It is a medical emergency that needs treatment right away.Overview · Symptoms · Causes
  14. [14]
    Hemorrhagic Stroke
    The two types of hemorrhagic strokes are intracerebral hemorrhage (within the brain) or subarachnoid hemorrhage (between the inner and outer layers of the ...
  15. [15]
    Cerebrovascular Disease: Types, Causes & Symptoms
    Subarachnoid hemorrhage (SAH). Transient ischemic attack (TIA) or mini stroke. Hereditary hemorrhagic telangiectasia (HHT). Moyamoya disease. Advertisement ...
  16. [16]
    Cerebrovascular Disease - AANS
    Transient Ischemic Attack (TIA). A TIA is a temporary cerebrovascular event that leaves no permanent damage. Most likely an artery to the brain is temporarily ...
  17. [17]
    10 Things You Should Know About Cerebral Small Vessel Disease
    Mar 28, 2024 · Cerebral small vessel disease (CSVD) refers to brain lesions secondary to pathological processes involving small blood vessels, primarily in white matter and ...
  18. [18]
    Cerebral Small Vessel Disease - PMC - PubMed Central - NIH
    Sep 25, 2018 · Neuroimaging features of CSVD include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, ...Missing: category | Show results with:category
  19. [19]
    New Insights Into Cerebrovascular Pathophysiology and Hypertension
    Mar 8, 2022 · A mean systolic blood pressure (SBP) >115 mm Hg explains 50% to 60% of the population attributable risk of ischemic stroke and over 70% of ...
  20. [20]
    Hypertension mechanisms causing stroke - PubMed
    Hypertension can cause stroke through many mechanisms. A high intraluminal pressure will lead to extensive alteration in endothelium and smooth muscle function.
  21. [21]
    2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC ...
    Aug 14, 2025 · The overarching blood pressure treatment goal is <130/80 mm Hg for all adults, with additional considerations for those who require ...
  22. [22]
    Influencing factors of stroke in patients with type 2 diabetes
    Jun 24, 2024 · Notably, individuals with diabetes face a two to four fold increased risk of stroke compared to their nondiabetic counterparts. Moreover, ...
  23. [23]
    Guideline-Directed Low-Density Lipoprotein Management in High ...
    Oct 9, 2014 · Among those presenting with a recurrent stroke, >45% had LDL>100 mg/dL. ... Large epidemiological studies showed an increased risk of ischemic ...
  24. [24]
    Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
    May 21, 2020 · Type 2 diabetes mellitus is a major risk factor for CVD. Because obesity is often associated with hypertension and dyslipidemia, many high-risk ...
  25. [25]
    Impact of Smoking Status on Stroke Recurrence
    Apr 6, 2019 · This study observed that patients who continued smoking after the index stroke had a nearly 2‐fold risk of stroke recurrence than nonsmokers.
  26. [26]
    Alcohol Use and Cardiovascular Disease: A Scientific Statement ...
    Jun 9, 2025 · Analyses confined to current drinkers have revealed a positive dose-response relationship between alcohol consumption and stroke risk, with ...
  27. [27]
    Atrial Fibrillation and Mechanisms of Stroke
    Jan 19, 2016 · Patients with AF face a strongly elevated risk of stroke—about 3- to 5-fold higher after adjustment for risk factors. AF has been ...
  28. [28]
    Stroke Risk Factors, Genetics, and Prevention | Circulation Research
    Feb 3, 2017 · Salt intake, for example, is associated with an increased risk of hypertension and stroke,110–114 whereas increased potassium intake is ...Modifiable Risk Factors · Inflammation And Infection · Targeted Lifestyle...
  29. [29]
    Accumulating Sedentary Time and Physical Activity From Childhood ...
    Mar 18, 2024 · Increased levels of sedentary behavior raise the risk of cardiovascular diseases, but little is known about the role of sedentary time and ...
  30. [30]
    Risk Factors for Stroke - CDC
    May 15, 2024 · The chance of having a stroke about doubles every 10 years after age 55. Although stroke is common among older adults, many people younger ...
  31. [31]
    Aging and ischemic stroke - PMC - NIH
    Aging is the most robust non-modifiable risk factor for incident stroke, which doubles every 10 years after age 55 years. Approximately three-quarters of all ...
  32. [32]
    Menopause and Stroke: An Epidemiologic Review - PMC - NIH
    Although overall age-adjusted stroke risk is higher in men than women, more strokes occur in women because of their longer life expectancy combined with very ...
  33. [33]
    Estimated 10-year Stroke Risk by Region and Race in the United ...
    African-Americans under age 75 have over twice the risk of stroke death than whites in the United States. Regardless of race, stroke death is ~50% higher in the ...
  34. [34]
    ETHNIC DIFFERENCES IN CARDIOVASCULAR DISEASE - PMC
    South Asians also have risks of stroke that are raised 1.5 fold compared to Europeans in the UK (fig 1). Stroke has been less well studied in South Asians ...
  35. [35]
    Apolipoprotein E ε4 Polymorphism as a Risk Factor for Ischemic Stroke
    Feb 3, 2022 · Rising studies indicate that the apolipoprotein E (APOE) gene is related to the susceptibility of ischemic stroke (IS).
  36. [36]
    Familial Hypercholesterolemia - GeneReviews® - NCBI Bookshelf
    Jan 2, 2014 · ... risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits ...
  37. [37]
    The epidemiology, evaluation and treatment of stroke in adults with ...
    Sickle cell disease (SCD) confers an increased risk of ischemic and primary hemorrhagic stroke. The association with stroke was first described by Sydentricker ...
  38. [38]
    [PDF] UNDERSTANDING STROKE IN WEST VIRGINIA
    An individual who has had one or more TIAs has nearly 10 times the risk of a stroke as ... Familial history of stroke and stroke risk: the Family Heart Study.<|control11|><|separator|>
  39. [39]
    Stroke Risk Factors, Genetics, and Prevention - PMC
    Diabetes. Diabetes is an independent risk factor for stroke with a 2-fold increased risk in stroke for diabetic patients, and stroke accounts for approximately ...
  40. [40]
    Ischemic Stroke - StatPearls - NCBI Bookshelf - NIH
    Feb 21, 2025 · Ischemic stroke, the most common type of stroke, is caused by thrombotic or embolic occlusion that reduces blood flow to the brain. The ...Ischemic Stroke · Pathophysiology · Treatment / ManagementMissing: hypoperfusion | Show results with:hypoperfusion
  41. [41]
    Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours ...
    Treatment with tPA in the 3-4.5 hour time-window is beneficial. It results in an increased rate of favorable outcome without adversely affecting mortality.
  42. [42]
    Differences in Vascular Risk Factors Between Etiological Subtypes ...
    Background— To understand the mechanisms of stroke and to target prevention, we need to know how risk factors differ between etiological subtypes.
  43. [43]
    Stroke Reperfusion Injury - StatPearls - NCBI Bookshelf - NIH
    May 16, 2024 · Stroke reperfusion injury refers to the exacerbation of cellular dysfunction and death upon restoration of blood flow to previously ischemic brain tissues.
  44. [44]
    Hemorrhagic Stroke - StatPearls - NCBI Bookshelf - NIH
    Hemorrhagic stroke is due to bleeding into the brain by the rupture of a blood vessel. ... [15] The other poor prognostic factors are hematoma expansion, ...
  45. [45]
    Cerebral Amyloid Angiopathy - StatPearls - NCBI Bookshelf - NIH
    Jun 5, 2023 · [1] The amyloid deposition results in fragile vessels that may manifest in lobar intracerebral hemorrhages (ICH).
  46. [46]
    Neuroimaging standards for research into small vessel disease ...
    Cerebral small vessel disease (SVD) is common during ageing and can present as stroke, cognitive decline, neurobehavioural symptoms, or functional impairment.Missing: 2024 2025
  47. [47]
    Reliability and validity of the total cerebral small vessel disease score
    Jun 26, 2025 · The Standards for Reporting Vascular Changes on Neuroimaging 2 (STRIVE-2) published in 2023 reinforced the need for summary measures of ...Missing: v2 | Show results with:v2
  48. [48]
    The pathogenesis of cerebral small vessel disease and vascular ...
    Cardinal neuroimaging features include small (<20 mm) infarcts or lacunes, cerebral microbleeds, white matter hyperintensities, enlarged perivascular spaces, ...
  49. [49]
    Hypertension and Cerebral Small Vessel Disease: A Review of the ...
    Sep 19, 2025 · Chronically elevated blood pressure in arterioles and capillaries causes endothelial dysfunction, lipohyalinosis, and fibrinoid necrosis of the ...Missing: pathogenesis | Show results with:pathogenesis
  50. [50]
    Cerebral small vessel disease: Pathological mechanisms and ...
    Aug 12, 2022 · Here, we review the underlying mechanisms of pathological characteristics in CSVD development, with a focus on endothelial dysfunction, blood- ...
  51. [51]
    unveiling the role of endothelial dysfunction in cerebral small vessel ...
    Cerebral small vessel disease (cSVD), a major contributor to stroke, cognitive decline, and vascular dementia, accounts for around 25% of ischemic strokes and ...
  52. [52]
  53. [53]
    Can white matter hyperintensities based Fazekas visual assessment ...
    Jul 10, 2024 · Our project utilized the Fazekas scale due to its advantage in evaluating PWMH and DWMH burden separately. Furthermore, they are increasingly ...Missing: cumulative | Show results with:cumulative<|control11|><|separator|>
  54. [54]
    Cerebral Small Vessel Disease: A Review Focusing on ...
    Total SVD burden is visually rated on a scale of 0 to 4. In this score, a point is allocated to each of the following: presence of lacunes, presence of CMB ...
  55. [55]
    Stroke Symptoms and Warning Signs
    F.A.S.T. Warning Signs of Stroke · F = Face Drooping – Does one side of the face droop or is it numb? Ask the person to smile. · A = Arm Weakness – Is one arm ...Women and Stroke · Stroke survivor dances at... · The F.A.S.T. Experience
  56. [56]
    Signs and Symptoms of Stroke - CDC
    Oct 24, 2024 · Sudden confusion, trouble speaking, or difficulty understanding speech. Sudden trouble seeing in one or both eyes.About · Treatment and Intervention · Risk Factors · About Sodium and Health
  57. [57]
    Seizures in Acute Stroke: Predictors and Prognostic Significance
    Seizures are common during the early phase after a stroke and have been reported to occur with a frequency of 2.5% to 5.7% within 14 days after a stroke.
  58. [58]
    Incidence of seizures in the acute phase of stroke - PubMed - NIH
    Jan 31, 2008 · The overall incidence of acute seizures after stroke was 3.1%, with a higher incidence seen in hemorrhagic stroke, younger patients, and those presenting with ...
  59. [59]
    Transient Ischemic Attack - StatPearls - NCBI Bookshelf - NIH
    A transient ischemic attack (TIA) is a medical emergency. It is defined as a transient episode of neurologic dysfunction due to focal brain, spinal cord, or ...
  60. [60]
    Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in ...
    Jan 19, 2023 · The 90-day stroke risk after transient ischemic attack can be as high as 17.8%, with almost half occurring within 2 days of the index event.
  61. [61]
    Posterior Versus Anterior Circulation Infarction | Stroke
    Nausea/vomiting (33.8% versus 10.4%; P<0.001) was the most frequent sign followed by ataxia (31.5% versus 5.4%; P<0.001), whereas other symptoms/signs with a ...
  62. [62]
    Long-term complications of stroke and secondary prevention - NIH
    Cognitive impairment. Cerebrovascular disease is increasingly recognised as a common cause of cognitive impairment and dementia in later life. Vascular dementia ...
  63. [63]
    Vascular Dementia - StatPearls - NCBI Bookshelf
    Oct 22, 2023 · MND requires an acquired decline in one or more cognitive domains, eg, attention, memory, executive function, language, or visuospatial ability, ...Vascular Dementia · History And Physical · Evaluation
  64. [64]
    Multiinfarct Dementia - an overview | ScienceDirect Topics
    Multiinfarct dementia (MID) is defined as a subtype of vascular dementia characterized by a stepwise progressive decline in cognitive function, resulting from ...
  65. [65]
    Hemiparesis | American Stroke Association
    Apr 12, 2024 · Hemiparesis after stroke is one-sided weakness or inability to move. Explore treatments, lifestyle changes and modifications that may help ...
  66. [66]
    Poststroke spasticity | STROKE MANUAL
    Jan 14, 2024 · Post-stroke spasticity (PSS) is one of the symptoms associated with upper motor neuron lesions. It is characterized by increased muscle tone ...Missing: hemiplegia | Show results with:hemiplegia
  67. [67]
    Interventions for sensory impairment in the upper limb after stroke
    Sensory deficits have been shown to predict poor functional outcome after stroke, including increased length of hospitalization, lower levels of discharge home, ...
  68. [68]
    Poststroke Depression: A Scientific Statement for Healthcare ...
    Dec 8, 2016 · Depression is common after stroke, affecting approximately one third of stroke survivors at any one time after stroke (compared with 5%–13% of ...
  69. [69]
    Poststroke Apathy | Stroke - American Heart Association Journals
    With a prevalence of 34.6%, poststroke apathy occurs as frequently as poststroke depression (33%) and poststroke dementia (21.0%–41.3%). Whereas these ...
  70. [70]
    Acute Stroke - StatPearls - NCBI Bookshelf - NIH
    Differentiate acute stroke from stroke mimics and ischemic etiology from hemorrhagic based on their varied clinical presentations, imaging findings, and ...
  71. [71]
    Guidelines for the Early Management of Patients With Acute ...
    Oct 30, 2019 · The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations in a single document for clinicians caring ...
  72. [72]
    Overview of Acute Ischemic Stroke Evaluation and Management - NIH
    Oct 16, 2021 · The NIHSS is a 42-point systematic assessment tool that should be performed within 10 min of the arrival of the patient to the emergency ...Missing: physical differential
  73. [73]
    Guidelines for the Early Management of Patients With Acute ...
    Jan 31, 2013 · The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke.<|control11|><|separator|>
  74. [74]
    Stroke mimics: incidence, aetiology, clinical features and treatment
    Mar 6, 2021 · Stroke is a medical emergency and presents with focal neurological deficits. Immediate evaluation, confirmation of diagnosis and treatment to ...Missing: hemiparesis | Show results with:hemiparesis
  75. [75]
    Diagnosis of acute stroke - PubMed - NIH
    Apr 15, 2015 · The most common conditions that can mimic a stroke are seizure, conversion disorder, migraine headache, and hypoglycemia.
  76. [76]
    Acute Stroke Diagnosis - PMC - PubMed Central - NIH
    Jul 1, 2009 · The NIHSS is one of the most common classifications of early stroke severity; it provides a structured neurologic examination that has ...
  77. [77]
    Sensitivity of Early Brain Computed Tomography to Exclude ...
    Jan 21, 2016 · The sensitivity of CT scans for detecting subarachnoid blood ranges from 90% to 100% when performed within the first 24 hours after symptom onset.
  78. [78]
    Computed tomography in acute intracerebral hemorrhage
    Nov 22, 2022 · The CINA® software does not measure hematoma volume, but can detect ICH with 95.6% accuracy, 91.4% sensitivity, and 97.5% specificity [130]. A ...
  79. [79]
    Stroke Imaging - StatPearls - NCBI Bookshelf - NIH
    CT, CT angiography (CTA), CT perfusion (CTP), CT venography (CTV), MRI, MR angiography (MRA), MR perfusion (MRP), ultrasonography, nuclear medicine, and ...Introduction · Computed Tomography · Magnetic Resonance · Nuclear Medicine
  80. [80]
    Comparison of MRI and CT for Detection of Acute Intracerebral ...
    Oct 20, 2004 · Although noncontrast CT has been considered the criterion standard for assessing intracerebral hemorrhage, formal studies have never been ...
  81. [81]
    Recommendations for Imaging of Acute Ischemic Stroke
    CT and MR imaging (MRI) are used for imaging of the density and intensity, respectively, of the cerebral parenchyma and its anatomic structure. The 3 roles of ...
  82. [82]
    The Role of Artificial Intelligence and Machine Learning in the ...
    Sep 27, 2025 · Application of artificial intelligence-based magnetic resonance imaging in diagnosis of cerebral small vessel disease. Hu X, Liu L, Xiong M ...
  83. [83]
    2022 Guideline for the Management of Patients With Spontaneous ...
    May 17, 2022 · This guideline recommends development of regional systems that provide initial intracerebral hemorrhage (ICH) care and the capacity, when appropriate, for ...
  84. [84]
    2021 Guideline for the Prevention of Stroke in Patients With Stroke ...
    May 24, 2021 · Patients with stroke are especially at risk for sedentary and prolonged sitting behaviors, and they should be encouraged to perform physical ...
  85. [85]
    Guidelines for Adult Stroke Rehabilitation and Recovery
    The occurrence of elbow contractures within the first year after stroke is associated with the presence of spasticity within the first 4 months. These ...
  86. [86]
    Interventions for Neural Plasticity in Stroke Recovery
    Aug 25, 2025 · This review highlights the need for a personalized, multidimensional approach to stroke rehabilitation. Continued research is necessary to ...
  87. [87]
    Case-fatality of acute ischemic stroke in stroke units of Latin ...
    In-hospital case-fatality was 9.42 %, 277 patients (10.2 %) died within 30 days, and 90-day case-fatality was relatively close at 353 patients (13.3 %).
  88. [88]
    Mortality after hemorrhagic stroke - Neurology.org
    The 30-day case fatality for SAH increased from 19.5% in men and 20.9% in women aged 20–49 years to 46.9% in men and 62.1% in women aged 80–89 years (figure 1B; ...
  89. [89]
    Trends and Disparities in Hemorrhagic Stroke and Hypertension ...
    Jul 21, 2025 · ICH accounts for 10% of all strokes in the United States, with mortality as high as 50% within 1 month (Virani et al. 2020; Fogelholm et al.
  90. [90]
    Hemorrhagic transformation of ischemic stroke - MedLink Neurology
    Hemorrhagic transformation occurs in ~10% of ischemic strokes, ranging from minor bleeding to severe hematomas, linked to worse outcomes and long-term…<|separator|>
  91. [91]
    Hemorrhagic Transformation After Ischemic Stroke - Frontiers
    Symptomatic hemorrhagic transformation (HT) is one of the complications most likely to lead to death in patients with acute ischemic stroke.Missing: cerebrovascular recurrent
  92. [92]
    High Mortality among 30-Day Readmission after Stroke - Frontiers
    The mortality rate for 30-day readmission after stroke is more than 2.5 times greater than index admissions and highest among those readmitted for recurrent ...<|separator|>
  93. [93]
    Hemorrhagic transformation and cerebral edema in acute ischemic ...
    Aug 9, 2025 · CA is known to be impaired in ischemic stroke, and its progressive disruption has been associated with both cerebral edema and hemorrhagic ...
  94. [94]
    The Association Between National Institutes of Health Stroke Scale ...
    Mar 1, 2024 · The findings indicate that higher baseline NIHSS scores correlate with poorer outcomes and increased mortality, particularly when scores exceed 20.
  95. [95]
    Risk Score for In-Hospital Ischemic Stroke Mortality Derived and ...
    Sep 27, 2010 · NIHSS score was strongly associated with mortality; median NIHSS score was 18 in those who died (interquartile range 11 to 24) compared with 4 ...<|separator|>
  96. [96]
    Global, Regional, and National Burden of Stroke, 1990–2021
    Oct 17, 2024 · The age-standardized mortality rate (ASMR) and DALY rates of stroke were 3.6× higher in the World Bank low-income countries than in the World ...
  97. [97]
    The rising global burden of stroke - PMC - NIH
    May 23, 2023 · Furthermore, over 80% of individuals in low-income countries (LICs) die within 3 years of a stroke compared with around 34% in high-income ...Missing: regions | Show results with:regions
  98. [98]
    Causes of Death by Level of Dependency at 6 Months After Ischemic ...
    Mar 5, 2009 · At the end of follow-up period, 1620 (47%) patients who were functionally dependent at 6 months after stroke onset had died vs 711 (28%) ...
  99. [99]
    [PDF] Background Concepts in Stroke Rehabilitation
    Faster recovery may be influenced by younger age, smaller lesions, and parenchymatous hemorrhages. Functional recovery primarily occurs within three months ...
  100. [100]
    Early Rehabilitation After Stroke: a Narrative Review - PMC - NIH
    Nov 7, 2017 · The evidence is mounting that for at least some deficits, initiation of rehabilitative strategies within the first 2 weeks of stroke is beneficial.Missing: aiding younger
  101. [101]
  102. [102]
    Pathophysiology, Diagnosis, Prognosis, and Prevention of ...
    May 17, 2024 · Two to fourteen percent of survivors develop poststroke epilepsy (PSE) following ischemic stroke and 10%–20% following hemorrhagic stroke.
  103. [103]
    Cognitive Impairment After Ischemic and Hemorrhagic Stroke
    May 1, 2023 · About 44% of individuals are impaired in global cognition 2 to 6 months after stroke. However, a large population of stroke survivors have ...
  104. [104]
    Genetic Underpinnings of Recovery After Stroke - PubMed
    Sep 13, 2019 · Genetic Underpinnings of Recovery After Stroke: An Opportunity for Gene Discovery, Risk Stratification, and Precision Medicine · Abstract.
  105. [105]
    2025 Heart Disease and Stroke Statistics: A Report of US and ...
    Jan 27, 2025 · The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions.
  106. [106]
    CNS small vessel disease: A clinical review - PMC - PubMed Central
    Prevalence increases with age, affecting about 5% of people aged 50 years to almost 100% of people older than 90 years.Discussion · Epidemiologic... · Pathogenesis
  107. [107]
    Trends in Stroke Incidence in High-Income Countries in the ... - NIH
    A previous systematic review of population-based studies suggested that stroke incidence in high-income countries decreased by 42% between the 1970s and early ...
  108. [108]
    What Is the Risk of Having a Stroke by Age Range? - Healthline
    Dec 2, 2022 · Overall, the most common age for stroke was 71.4 years in men and 76.9 years in women, according to a 2021 studyTrusted Source . Older ...Missing: peak predominance
  109. [109]
    Hypertension in West Africa: a systematic review and meta-analysis ...
    Oct 1, 2025 · This systematic review and meta-analysis of 30 studies (n = 70,212) reveals a staggering 33.8% hypertension prevalence. Also, nearly 1 in 3 ...<|separator|>
  110. [110]
    The burden of stroke in Africa: a glance at the present and a glimpse ...
    Overall crude annual stroke incidence rates were 94.5 per 100 000 in Hai and 107.9 per 100 000 in Dar-es-Salaam (Table 1). When age-standardised to the WHO ...
  111. [111]
    Projected Global Trends in Ischemic Stroke Incidence, Deaths and ...
    Apr 24, 2023 · The global age-standardized incidence rate of ischemic stroke was projected to increase to 89.32 per 100 000 population in 2030 (EAPC=0.89), ...
  112. [112]
    Socioeconomic status and stroke incidence, prevalence, mortality ...
    Oct 24, 2019 · Further, the rates of stroke mortality and burden were significantly higher in lower SES regions compared with HICs.
  113. [113]
    Socioeconomic Status and Stroke: A Review of the Latest Evidence ...
    Dec 19, 2024 · First-month mortality after stroke was linked to lower income in Catalonia, Zanzibar, and the United States. In Catalonia (n=16 344), lower- ...
  114. [114]
    Mind the Gap: Performance Differences Between Rural and Urban ...
    Nov 14, 2024 · Stroke incidence is up to 30% higher in rural areas compared to urban areas. ... In-hospital mortality was similar across rural and urban stroke ...
  115. [115]
    Annual exposure to PM10 is related to cerebral small vessel disease ...
    Nov 16, 2022 · We demonstrated that annual exposure to PM10 was associated with WMH volume and presence of SLI in Asian adults. This finding suggests the ...
  116. [116]
    Ambient air pollution exposure in relation to cerebral small vessel ...
    These findings suggest that a positive link between air pollutants exposure and neuroimaging markers of CSVD in the Chinese population.
  117. [117]
    The burden of heat-related stroke mortality under climate change ...
    Climate change will exacerbate the burden of heat-related stroke mortality but with considerable geographical heterogeneity in East Asia.Missing: cerebrovascular | Show results with:cerebrovascular
  118. [118]
    Long-term Risk of Heart Attack, Stroke and Death Doubles with ...
    Dec 18, 2024 · The study found that people with any type of COVID-19 infection were twice as likely to have a major cardiac event, such as heart attack, stroke or even death, ...
  119. [119]
    National Diabetes Statistics Report - CDC
    May 15, 2024 · 368,000 for ischemic heart disease (15.7 per 1,000 adults with diabetes). 321,000 for stroke (13.7 per 1,000 adults with diabetes). 160,000 for ...Diabetes Data and Statistics · Appendix A: Detailed Tables
  120. [120]
    Excess Stroke in Mexican Americans Compared with Non-Hispanic ...
    Mexican Americans experience a substantially greater ischemic stroke and intracerebral hemorrhage incidence compared with non-Hispanic Whites.
  121. [121]
    Epidemiology of Ischemic Stroke in Patients With Diabetes
    Diabetes is clearly one of the most important risk factors for ischemic stroke, especially in those patients less than 65 years of age. We estimate that 37–42% ...
  122. [122]
    2024 Guideline for the Primary Prevention of Stroke
    Oct 21, 2024 · The 2024 primary prevention of stroke guideline provides recommendations based on current evidence for strategies to prevent stroke throughout the life span.
  123. [123]
    Tobacco: Health benefits of smoking cessation
    Feb 25, 2020 · 5 years, your stroke risk is reduced to that of a nonsmoker 5 to 15 years after quitting. 10 years, your risk of lung cancer falls to about half ...
  124. [124]
    Mediterranean Diet Reduces Risk of Incident Stroke in a Population ...
    Sep 20, 2018 · Participants with highest adherence to the MDS had a 13% reduced risk of stroke compared with those in the lowest MDS quartile (quartile 4 ...
  125. [125]
    2019 ACC/AHA Guideline on the Primary Prevention of ...
    Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol levels (≥190 mg/dL), those ...
  126. [126]
    Statin Use for the Primary Prevention of Cardiovascular Disease in ...
    Aug 23, 2022 · The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD ...Missing: pharmacological | Show results with:pharmacological
  127. [127]
    Recommendation: Aspirin Use to Prevent Cardiovascular Disease
    Apr 26, 2022 · The evidence showed that aspirin use for primary prevention of CVD was associated with a decreased risk of myocardial infarction and stroke but ...
  128. [128]
    Recommendation: Hypertension in Adults: Screening - uspstf
    Apr 27, 2021 · The USPSTF suggests annual screening for hypertension in adults 40 years or older and for adults at increased risk for hypertension.<|separator|>
  129. [129]
    World Stroke Campaign
    We work to improve public awareness and understanding of stroke with a focus on stroke prevention, symptom awareness and the needs of stroke survivors.
  130. [130]
    Air Pollution and Stroke: An Emerging Challenge From Cardio ...
    Jun 27, 2025 · Indeed, air pollution was found to be involved in almost every transition stage for the development of cardio‐cerebrovascular multimorbidity, ...
  131. [131]
    Summary of Revisions: Standards of Care in Diabetes—2025
    Dec 9, 2024 · The 2025 Standards of Care contains, in addition to many minor changes that clarify recommendations or reflect new evidence, more substantive revisions ...Missing: emerging pollution cerebrovascular
  132. [132]
    Residual Stroke Risk Among Patients With Atrial Fibrillation ...
    Aug 27, 2024 · The benefit of anticoagulation to prevent stroke in atrial fibrillation (AF) is firmly established. Warfarin reduces stroke risk by two thirds, ...
  133. [133]
    Carotid Artery Disease: Then and Now | Stroke
    Mar 5, 2024 · For symptomatic patients, revascularization is appropriate for patients with ≥50% stenosis and the clinical characteristics of the patients ...
  134. [134]
    Updated Perspectives on Lifestyle Interventions as Secondary ... - NIH
    Mar 19, 2024 · This review underlines the benefits of adhering to lifestyle modifications as the most effective secondary stroke prevention measure.
  135. [135]
    CYP2C19 Genotype–Guided Antiplatelet Therapy in Precision ...
    Sep 25, 2025 · Antiplatelet therapy is a cornerstone of secondary prevention of ischemic stroke; however, clopidogrel, 1 of the most commonly prescribed ...
  136. [136]
    2023 Guideline for the Management of Patients With Aneurysmal ...
    Unlike other stroke subtypes, aSAH affects individuals in their working years, with a mean age of 55 years. Although the cause for cerebral aneurysms and aSAH ...
  137. [137]
    The Society for Vascular Surgery clinical practice guidelines on the ...
    Mar 19, 2020 · 5.2: We suggest postembolization surveillance every 1 to 2 years with axial imaging to assess for vascular remodeling and evidence of aneurysm ...